Bio Time, Inc. (NYSE: BTX) and its subsidiaries are leveraging a broad IP portfolio to facilitate the development and use of cell-based therapies and gene marker-based molecular diagnostics for major diseases and degenerative conditions for which there presently are no cures. The lead clinical programs of BioTime and its subsidiaries include OpRegen®, currently in a phase I/IIa trial for the treatment of the dry form of age-related macular degeneration; AST-OPC1, currently in a phase I/IIa trial for spinal cord injuries; Renevia™, currently in a pivotal trial in Europe as an injectable matrix for the engraftment of transplanted cells to treat HIV-related lipoatrophy; and cancer diagnostics, nearing the completion of initial clinical studies for the detection of lung, bladder, and breast cancers. AST-VAC2, a cancer vaccine, is in the pre-clinical trial stage. For more information, visit the company’s website at www.biotimeinc.com.